AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine

Chiou Tsun Tsai, Pei Ming Yang, Ting Rong Chern, Shu Hui Chuang, Jung Hsin Lin, Lars Klemm, Markus Müschen, Ching Chow Chen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Activation-induced cytidine deaminase (AID) was originally identified as an inducer of somatic hypermutation (SHM) and class switch recombination (CSR) in immunoglobulin genes. However, AID can also cause mutations in host genes and contribute to cancer progression and drug resistance. In this study, molecular docking showed the interaction of free 5-aza-CdR and Zebularine (Zeb) with AID. However, only 5-aza-CdR-incorporated ssDNA bound to the active site of AID and inhibited AID expression through proteasomal degradation. 5-aza-CdR demonstrated cytotoxicity against AID-positive and -negative hematopoietic cancer cells. In contrast, Zeb exhibited a cytotoxic effect only in AID-negative cells due to its inability to inhibit AID expression. This differential effect might be due to the DNMT1 stabilization induced by AID, thus restricting the ability of Zeb to deplete DNMT1 and induce tumor suppressor genes (TSGs), such as p21, in AID-positive cells. Moreover, the in vivo anticancer effect of 5-aza-CdR but not Zeb in AID-positive hematopoietic cancer cells was demonstrated. The study not only displays the association of AID and DNMT1 and identifies a novel biological function of AID, but also provides novel information regarding the use of DNMT inhibitors to treat AID-positive hematopoietic cancers.

Original languageEnglish
Pages (from-to)211-223
Number of pages13
JournalOncotarget
Volume5
Issue number1
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Deoxycytidine
Down-Regulation
pyrimidin-2-one beta-ribofuranoside
AICDA (activation-induced cytidine deaminase)
Neoplasms
Immunoglobulin Genes
Tumor Suppressor Genes
Drug Resistance
Genetic Recombination

Keywords

  • 5-aza-CdR
  • AID
  • DNMT1
  • Zebularine

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Cite this

Tsai, C. T., Yang, P. M., Chern, T. R., Chuang, S. H., Lin, J. H., Klemm, L., ... Chen, C. C. (2014). AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget, 5(1), 211-223.

AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. / Tsai, Chiou Tsun; Yang, Pei Ming; Chern, Ting Rong; Chuang, Shu Hui; Lin, Jung Hsin; Klemm, Lars; Müschen, Markus; Chen, Ching Chow.

In: Oncotarget, Vol. 5, No. 1, 2014, p. 211-223.

Research output: Contribution to journalArticle

Tsai, CT, Yang, PM, Chern, TR, Chuang, SH, Lin, JH, Klemm, L, Müschen, M & Chen, CC 2014, 'AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine', Oncotarget, vol. 5, no. 1, pp. 211-223.
Tsai CT, Yang PM, Chern TR, Chuang SH, Lin JH, Klemm L et al. AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. Oncotarget. 2014;5(1):211-223.
Tsai, Chiou Tsun ; Yang, Pei Ming ; Chern, Ting Rong ; Chuang, Shu Hui ; Lin, Jung Hsin ; Klemm, Lars ; Müschen, Markus ; Chen, Ching Chow. / AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine. In: Oncotarget. 2014 ; Vol. 5, No. 1. pp. 211-223.
@article{c2c2f4301c094a5397e8599218e316e6,
title = "AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine",
abstract = "Activation-induced cytidine deaminase (AID) was originally identified as an inducer of somatic hypermutation (SHM) and class switch recombination (CSR) in immunoglobulin genes. However, AID can also cause mutations in host genes and contribute to cancer progression and drug resistance. In this study, molecular docking showed the interaction of free 5-aza-CdR and Zebularine (Zeb) with AID. However, only 5-aza-CdR-incorporated ssDNA bound to the active site of AID and inhibited AID expression through proteasomal degradation. 5-aza-CdR demonstrated cytotoxicity against AID-positive and -negative hematopoietic cancer cells. In contrast, Zeb exhibited a cytotoxic effect only in AID-negative cells due to its inability to inhibit AID expression. This differential effect might be due to the DNMT1 stabilization induced by AID, thus restricting the ability of Zeb to deplete DNMT1 and induce tumor suppressor genes (TSGs), such as p21, in AID-positive cells. Moreover, the in vivo anticancer effect of 5-aza-CdR but not Zeb in AID-positive hematopoietic cancer cells was demonstrated. The study not only displays the association of AID and DNMT1 and identifies a novel biological function of AID, but also provides novel information regarding the use of DNMT inhibitors to treat AID-positive hematopoietic cancers.",
keywords = "5-aza-CdR, AID, DNMT1, Zebularine",
author = "Tsai, {Chiou Tsun} and Yang, {Pei Ming} and Chern, {Ting Rong} and Chuang, {Shu Hui} and Lin, {Jung Hsin} and Lars Klemm and Markus M{\"u}schen and Chen, {Ching Chow}",
year = "2014",
language = "English",
volume = "5",
pages = "211--223",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "1",

}

TY - JOUR

T1 - AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine

AU - Tsai, Chiou Tsun

AU - Yang, Pei Ming

AU - Chern, Ting Rong

AU - Chuang, Shu Hui

AU - Lin, Jung Hsin

AU - Klemm, Lars

AU - Müschen, Markus

AU - Chen, Ching Chow

PY - 2014

Y1 - 2014

N2 - Activation-induced cytidine deaminase (AID) was originally identified as an inducer of somatic hypermutation (SHM) and class switch recombination (CSR) in immunoglobulin genes. However, AID can also cause mutations in host genes and contribute to cancer progression and drug resistance. In this study, molecular docking showed the interaction of free 5-aza-CdR and Zebularine (Zeb) with AID. However, only 5-aza-CdR-incorporated ssDNA bound to the active site of AID and inhibited AID expression through proteasomal degradation. 5-aza-CdR demonstrated cytotoxicity against AID-positive and -negative hematopoietic cancer cells. In contrast, Zeb exhibited a cytotoxic effect only in AID-negative cells due to its inability to inhibit AID expression. This differential effect might be due to the DNMT1 stabilization induced by AID, thus restricting the ability of Zeb to deplete DNMT1 and induce tumor suppressor genes (TSGs), such as p21, in AID-positive cells. Moreover, the in vivo anticancer effect of 5-aza-CdR but not Zeb in AID-positive hematopoietic cancer cells was demonstrated. The study not only displays the association of AID and DNMT1 and identifies a novel biological function of AID, but also provides novel information regarding the use of DNMT inhibitors to treat AID-positive hematopoietic cancers.

AB - Activation-induced cytidine deaminase (AID) was originally identified as an inducer of somatic hypermutation (SHM) and class switch recombination (CSR) in immunoglobulin genes. However, AID can also cause mutations in host genes and contribute to cancer progression and drug resistance. In this study, molecular docking showed the interaction of free 5-aza-CdR and Zebularine (Zeb) with AID. However, only 5-aza-CdR-incorporated ssDNA bound to the active site of AID and inhibited AID expression through proteasomal degradation. 5-aza-CdR demonstrated cytotoxicity against AID-positive and -negative hematopoietic cancer cells. In contrast, Zeb exhibited a cytotoxic effect only in AID-negative cells due to its inability to inhibit AID expression. This differential effect might be due to the DNMT1 stabilization induced by AID, thus restricting the ability of Zeb to deplete DNMT1 and induce tumor suppressor genes (TSGs), such as p21, in AID-positive cells. Moreover, the in vivo anticancer effect of 5-aza-CdR but not Zeb in AID-positive hematopoietic cancer cells was demonstrated. The study not only displays the association of AID and DNMT1 and identifies a novel biological function of AID, but also provides novel information regarding the use of DNMT inhibitors to treat AID-positive hematopoietic cancers.

KW - 5-aza-CdR

KW - AID

KW - DNMT1

KW - Zebularine

UR - http://www.scopus.com/inward/record.url?scp=84893874694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893874694&partnerID=8YFLogxK

M3 - Article

C2 - 24457556

AN - SCOPUS:84893874694

VL - 5

SP - 211

EP - 223

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -